The size classes of the Epstein-Barr virus(EBV)-induced nuclear antigen (EBNA) have been determined in EBV-carrying sublines of two originally EBV-negative Burkitt lymphomas, converted in vitro by two different EBV substrains, and in somatic hybrids between two EBV-carrying cell lines or between an EBV-positive and an EBV-negative line. Partially purified EBNA components were detected by Western blotting and subsequent exposure to antiserum/alkaline-phosphatase-coupled protein A complexes. Converted Ramos and BJAB sublines contained the main EBNA components characteristic for the virus donor strain. The EBNA components of the Ramos and BJAB cells converted by P3HR-1 virus were similar to each other and to the components of the P3HR-1 donor cell, whereas the EBNA of the cells converted by B95–8 virus resembled the B95–8 donor line. It was concluded that the size variation of EBNA is determined by the viral genome. The parental lines of the somatic hybrids studied (Raji, P3HR-1, Namalwa and Daudi) contained EBNA components of different molecular weight (MW) classes. The higher MW forms ranged from 70K to 80K. Several distinctive lower MW components also were present. The somatic hybrids expressed the main EBNA components of both parental lines. Hybrids between EBV-carrying and EBV-genome-negative lines contained the characteristic EBNA component of the EBV-positive parent. It was concluded that the size variation of EBNA is under strict genetic control which prevails in the hybrids in a codominant fashion.

Keywords:
Epstein-Barr virus, Epstein-Barr virus nuclear antigen
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.